Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema

Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study ID
NCT02979665
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab Ophthalmic — DRUG
    Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss and diabetic macular edema (DME).

Study Details

anti-VEGF therapy is an established method to control leakage and abnormal growth of retinal blood vessels. Questions on the long-term effect on the retina, intraocular pressure and on the overall retinal perfusion from these treatments remain to be answered. The purpose of the study was to evaluate changes in the retina following anti-VEGF treatment over time, using structural and functional diagnostic tests.

Key Dates

First listed
Dec 1, 2016
Start date
Sep 30, 2014
Status verified
Apr 2019
Primary completion
Aug 31, 2017
Completion
Aug 31, 2017

Study Design

Enrollment
51 participants (actual)

Arms

  • Arm: Ranibizumab Ophthalmic
    DME consults requiring anti-VEGF treatment
  • Arm: Control
    DME consults not requiring anti-VEGF

Primary Outcome Measure

Effects of anti-VEGF drugs on intraocular pressure (mmHg) [ Time Frame: 2 year ]

Related Studies